Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Bilthoven – page 7

1 718 clinical trials in Bilthoven, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Bilthoven at a glance
1 718
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 718 trials in Bilthoven

Open in trial search

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Amsterdam UMC Stichting

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immatics US Inc.

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study of Sacituzumab Govitecan and Bevacizumab for Treating Brain Metastases in Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:University Hospital Maastricht

Dose-Reduced Oxaliplatin and Drug Combination Study for Older Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Recruiting

Study of ATX-898 alone and in drug combination for patients with advanced solid tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Antares Therapeutics Inc.

Study of ZL-1310, BI 764532 and atezolizumab in patients with advanced small cell lung cancer and neuroendocrine tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Herpes zoster

Recruiting

Non‑inferiority of fractional varicella zoster virus glycoprotein E vaccine (AS01B) versus recombinant varicella zoster virus glycoprotein E vaccine in adults with shingles

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Varicella zoster virus, glycoprotein E, adjuvanted with AS01B
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Bilthoven

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on optimizing vaccine effectiveness against multiple infectious diseases, including studies on meningococcal disease and influenza in different age groups.

  • Meningococcal Disease Prevention
  • Influenza Vaccination Timing
  • Early Measles Protection

Novel approaches include investigating optimal vaccination timing and early immunization strategies for enhanced protection.

02 Oncology Research

Advanced studies in breast cancer treatment, examining innovative therapeutic combinations for hormone receptor-positive cases.

  • Hormone Receptor Positive Breast Cancer
  • CDK 4/6 Inhibition Therapy
  • Sequential Treatment Strategies

Investigations focus on optimizing treatment sequences to improve progression-free survival rates.

03 Surgical Interventions

Clinical research examining surgical treatments combined with antibiotic therapy for improved patient outcomes.

  • Perianal Abscess Management
  • Combined Treatment Approaches
  • Fistula Prevention

Studies aim to enhance surgical outcomes through innovative combination therapies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.